1. Home
  2. ZYME vs TMP Comparison

ZYME vs TMP Comparison

Compare ZYME & TMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • TMP
  • Stock Information
  • Founded
  • ZYME 2003
  • TMP 1836
  • Country
  • ZYME United States
  • TMP United States
  • Employees
  • ZYME N/A
  • TMP N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • TMP Major Banks
  • Sector
  • ZYME Health Care
  • TMP Finance
  • Exchange
  • ZYME Nasdaq
  • TMP Nasdaq
  • Market Cap
  • ZYME 867.6M
  • TMP 878.2M
  • IPO Year
  • ZYME 2017
  • TMP N/A
  • Fundamental
  • Price
  • ZYME $13.30
  • TMP $66.57
  • Analyst Decision
  • ZYME Buy
  • TMP Buy
  • Analyst Count
  • ZYME 7
  • TMP 2
  • Target Price
  • ZYME $19.50
  • TMP $69.00
  • AVG Volume (30 Days)
  • ZYME 494.5K
  • TMP 55.0K
  • Earning Date
  • ZYME 07-31-2025
  • TMP 07-25-2025
  • Dividend Yield
  • ZYME N/A
  • TMP 3.71%
  • EPS Growth
  • ZYME N/A
  • TMP 980.13
  • EPS
  • ZYME N/A
  • TMP 5.16
  • Revenue
  • ZYME $93,384,000.00
  • TMP $297,067,000.00
  • Revenue This Year
  • ZYME $44.71
  • TMP $13.79
  • Revenue Next Year
  • ZYME $34.57
  • TMP $6.90
  • P/E Ratio
  • ZYME N/A
  • TMP $12.94
  • Revenue Growth
  • ZYME 85.05
  • TMP 40.19
  • 52 Week Low
  • ZYME $9.03
  • TMP $52.73
  • 52 Week High
  • ZYME $17.70
  • TMP $79.01
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 61.39
  • TMP 57.62
  • Support Level
  • ZYME $12.75
  • TMP $66.22
  • Resistance Level
  • ZYME $13.80
  • TMP $67.89
  • Average True Range (ATR)
  • ZYME 0.42
  • TMP 1.33
  • MACD
  • ZYME 0.07
  • TMP 0.24
  • Stochastic Oscillator
  • ZYME 79.88
  • TMP 65.16

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About TMP Tompkins Financial Corporation

Tompkins Financial Corp is a Financial Holding Company. It has three business segments, consisting of banking, insurance and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Insurance is comprised of property and casualty insurance services and employee benefit consulting. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates majority of its revenue from Banking segment.

Share on Social Networks: